Susan Graves, MD
Family Medicine · Brookline, MONPI 1861581084
Payments from drug & device makers
Across 241 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$667
- AstraZeneca$596
- AbbVie$402
- Pfizer$352
- Lilly USA, LLC$349
- GSK$260
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,893100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $667 |
| AstraZeneca | 25 | $596 |
| AbbVie | 22 | $402 |
| Pfizer | 23 | $352 |
| Lilly USA, LLC | 22 | $349 |
| GSK | 19 | $260 |
| Johnson & Johnson(2 entities) | 5 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $130 |
| Amgen | 7 | $129 |
| Boehringer Ingelheim | 8 | $119 |
| Abbott | 5 | $108 |
| Lundbeck LLC | 4 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Dexcom, Inc. | 3 | $45 |
| Astellas Pharma US Inc | 2 | $39 |
| Viatris Specialty LLC | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Exact Sciences | 2 | $33 |
| Novartis | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Bayer | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Circassia Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Merck | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Apria Healthcare LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,893 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $97,855 |
| OzempicSemaglutide | 63 | $77,950 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $74,395 |
| JardianceEmpagliflozin | 73 | $59,660 |
| FarxigaDapagliflozin Propanediol | 68 | $56,056 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $43,580 |
| TrulicityDulaglutide | 42 | $40,562 |
| RybelsusSemaglutide | 27 | $32,131 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 96 | $30,107 |
| JanuviaSitagliptin Phosphate | 41 | $30,076 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 133 | $29,069 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $28,761 |
| MounjaroTirzepatide | 22 | $27,679 |
| ProliaDenosumab | 11 | $18,547 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $14,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $352 | $127,963215 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $667 | $123,990101 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat, Tradjenta, Synjardy | $119 | $120,120152 claims |
| GSKTrelegy Ellipta, Shingrix | $260 | $103,464234 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $349 | $68,24164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $596 | $63,22979 claims |
| MerckJanuvia | $14 | $30,07641 claims |
| AmgenProlia | $129 | $18,54711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Brookline
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.